Eli Lilly and Company (LLY), Monday announced a deal with Ajax Therapeutics, Inc., agreeing to acquire the company along with its lead asset, AJ1-11095, an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in patients with myelofibrosis.
As per the deal, Ajax shareholders would receive up to $2.3 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.
"As a founding strategic investor in Ajax, Lilly has long believed in the approach and is excited about the potential for AJ1-11095 to deliver deeper and more durable efficacy than available treatments with a tolerability profile that would allow for patients to remain on therapy longer and be used across both the first- and second-line settings," said Jacob Van Naarden, executive vice president and president of Lilly Oncology and head of corporate business development.
In the pre-market hours, LLY is trading at $884.65, up 0.05 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.